Drug Improves Induction Chemo for Head and Neck Cancers
For patients with advanced head and neck cancers who receive an initial treatment of chemotherapy prior to other therapies, three drugs appear to be better than two. Patients who received docetaxel (Taxotere) in addition to the standard combination of cisplatin and fluorouracil had better outcomes than those taking cisplatin and fluorouracil alone, according to findings in the October 25 New England Journal of Medicine.
The results are from two randomized clinical trials that evaluated the addition of docetaxel to standard chemotherapy for patients receiving induction (or neoadjuvant) treatment. This treatment is given before radiation-based therapy, as was the case in the two reported clinical trials, and/or surgery. Read more
HIV/AIDS Research at NCI: A Record of Sustained Excellence
The human immunodeficiency virus (HIV) and the disease it causes, Acquired Immune Deficiency Syndrome (AIDS), announced itself in the United States in 1981, in the form of a small, sudden uptick in reports of a rare cancer, Kaposi sarcoma (KS), and a rare form of pneumonia among young gay men in New York and San Francisco. That same year, in the NIH Clinical Center, NCI physicians treated the first patient with this deadly, yet-to-be-named disease.
NCI's history will forever be intertwined with that of HIV and AIDS. NCI scientists were at the forefront of the effort to identify HIV as the cause of AIDS, characterize how it hijacked cellular machinery, and, in turn, develop the first treatments for it. Read more